IL321935A - Treatment of cd20-positive b-cell lymphoma with obituzumab - Google Patents

Treatment of cd20-positive b-cell lymphoma with obituzumab

Info

Publication number
IL321935A
IL321935A IL321935A IL32193525A IL321935A IL 321935 A IL321935 A IL 321935A IL 321935 A IL321935 A IL 321935A IL 32193525 A IL32193525 A IL 32193525A IL 321935 A IL321935 A IL 321935A
Authority
IL
Israel
Prior art keywords
obinutuzumab
hour
administration
cycle
pharmaceutical composition
Prior art date
Application number
IL321935A
Other languages
Hebrew (he)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=64362606&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL321935(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of IL321935A publication Critical patent/IL321935A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)

Claims (15)

19 WO 2019/017499 PCT/JP2018/038924
1. [Claim 1] Claims A pharmaceutical composition for treating CD20-positive B-cell lymphoma comprising obinutuzumab, which is intravenously drip infused at 1000 mg of obinutuzumab per administration, and given according to the administration speeds of the following (a) and (b) in two or more cycles:(a) the maximum administration speed in the first cycle is equal to or more than 200 mg of obinutuzumab an hour, preferably equal to or more than 300 mg of obinutuzumab an hour, more preferably equal to or more than 400 mg of obinutuzumab an hour;
2. [Claim 2] (b) the maximum administration speed in the second or later cycle is equal to or more than 700 mg of obinutuzumab an hour, preferably equal to or more than 800 mg of obinutuzumab an hour, more preferably equal to or more than 900 mg of obinutuzumab an hour. The pharmaceutical composition according to claim 1, wherein a duration per administration in the second or later cycle is within 180
3. [Claim 3] minutes, preferably within 150 minutes, more preferably within 120minutes, the most preferably within 90 minutes.The pharmaceutical composition according to claim 1 or 2, which is ad- ministered 3 times in the first cycle, and once a cycle in the second or
4. [Claim 4]later cycle.The pharmaceutical composition according to claim 3, wherein the first administration in the first cycle is initiated at a speed of 50 mg of obin- utuzumab an hour, and the second or later administration in the first
5. [Claim 5]cycle is initiated at a speed of 100 mg of obinutuzumab an hour.The pharmaceutical composition according to any one of claims 1 to 4, wherein the administration speed in the second or later cycle is increased to 700 mg of obinutuzumab an hour or faster, preferably to 800 mg of obinutuzumab an hour or faster, more preferably up to 9mg of obinutuzumab an hour.
6. [Claim 6] The pharmaceutical composition according to any one of claims 1 to 5, wherein, in (b), the pharmaceutical composition is given according to at least one of the following (c) to (e) conditions:(c) if no infusion reaction of Grade 3 or above appeared with the last three administrations, and the number of lymphocytes in peripheral blood before administration is less than 5000/uL, administration is carried out at 100 mg/hour for 30 minutes. If no infusion reaction is 20 WO 2019/017499 PCT/JP2018/038924 observed all that time, the speed can be increased to 900 mg/hour. Depending on the condition of the patient, the speed is decreased to, for example, the administration speed in cycle 1, as appropriate.(d) if an infusion reaction of Grade 1/2 appeared, administration is restarted at half the speed before administration was stopped. If no infusion reaction is observed in 30 minutes, the speed can be increased to 900 mg/hour.(e) if an infusion reaction of Grade 3, administration is restarted at 2mg/hour or lower. If no infusion reaction is observed in 30 minutes, the speed can be increased by 50 mg/hour every 30 minutes to a maximum of 400 mg/hour.
7. [Claim 7] The pharmaceutical composition according to any one of claims 1 to 6, which is administered on days 1, 8 and 15 in the first cycle, and on day in the second or later cycle.
8. [Claim 8] The pharmaceutical composition according to any one of claims 1 to 7, wherein each cycle is 3 weeks.
9. [Claim 9] The pharmaceutical composition according to any one of claims 1 to 7, which is used in combination with at least one of other anti-tumor agents, and whose administration cycle is synchronized with a dosing cycle of said at least one of other anti-tumor agents, wherein the dosing cycle is 4 weeks a cycle.
10. [Claim 10] The pharmaceutical composition according to claim 9, wherein said at least one of other anti-tumor agents is selected from CHOP, CVP, ben- damustine, fludarabine, lenalidomide, an anti-PD-1 antibody, and an anti-PD-Ll antibody.
11. [Claim 11] The pharmaceutical composition according to any one of claims 1 to 10, wherein the pharmaceutical composition is given every two months for two years as maintenance monotherapy after said two or more cycles.
12. [Claim 12] The pharmaceutical composition according to any one of claims 1 to 11, wherein the obinutuzumab concentration in infusion fluid when in- travenously drip infused is 10 to 40 mg/mL, preferably 20 to 30 mg/ mL, more preferably 25 mg/mL.
13. [Claim 13] The pharmaceutical composition according to any one of claims 1 to 12, further comprising a trehalose hydrate, L-histidine, L-histidine hy- drochloride hydrate, or polyoxyethylene (160) polyoxypropylene (30) glycol as an additive.
14. [Claim 14] Use of obinutuzumab in a manufacture of a pharmaceutical com- 21 WO 2019/017499 PCT/JP2018/038924 position for treating CD20-positive B-cell lymphoma comprising obin- utuzumab, wherein the composition is intravenously drip infused at 1000 mg of obinutuzumab per administration, and given according to the administration speeds of the following (a) and (b) in two or more cycles:(a) the maximum administration speed in the first cycle is equal to or more than 200 mg of obinutuzumab an hour, preferably equal to or more than 300 mg of obinutuzumab an hour, more preferably equal to or more than 400 mg of obinutuzumab an hour;(b) the maximum administration speed in the second or later cycle is equal to or more than 700 mg of obinutuzumab an hour, preferably equal to or more than 800 mg of obinutuzumab an hour, more preferably equal to or more than 900 mg of obinutuzumab an hour.
15. [Claim 15] A method for treating CD20-positive B-cell lymphoma by a pharma-ceutical composition comprising obinutuzumab, wherein the com- position is intravenously drip infused at 1000 mg of obinutuzumab per administration, and given according to the administration speeds of the following (a) and (b) in two or more cycles:(a) the maximum administration speed in the first cycle is equal to or more than 200 mg of obinutuzumab an hour, preferably equal to or more than 300 mg of obinutuzumab an hour, more preferably equal to or more than 400 mg of obinutuzumab an hour;(b) the maximum administration speed in the second or later cycle is equal to or more than 700 mg of obinutuzumab an hour, preferably equal to or more than 800 mg of obinutuzumab an hour, more preferably equal to or more than 900 mg of obinutuzumab an hour.
IL321935A 2017-10-19 2018-10-19 Treatment of cd20-positive b-cell lymphoma with obituzumab IL321935A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762574297P 2017-10-19 2017-10-19
PCT/JP2018/038924 WO2019017499A2 (en) 2017-10-19 2018-10-19 A pharmaceutical composition

Publications (1)

Publication Number Publication Date
IL321935A true IL321935A (en) 2025-09-01

Family

ID=64362606

Family Applications (2)

Application Number Title Priority Date Filing Date
IL273909A IL273909B2 (en) 2017-10-19 2018-10-19 Treatment of CD20-positive B-cell lymphoma with obinutuzumab
IL321935A IL321935A (en) 2017-10-19 2018-10-19 Treatment of cd20-positive b-cell lymphoma with obituzumab

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IL273909A IL273909B2 (en) 2017-10-19 2018-10-19 Treatment of CD20-positive B-cell lymphoma with obinutuzumab

Country Status (14)

Country Link
US (2) US12129304B2 (en)
EP (2) EP3697818B1 (en)
JP (2) JP6860652B2 (en)
KR (3) KR20260011191A (en)
CN (2) CN111212854A (en)
AU (2) AU2018303836B2 (en)
BR (1) BR112020007731A2 (en)
CA (1) CA3079374A1 (en)
ES (1) ES3005784T3 (en)
IL (2) IL273909B2 (en)
MX (2) MX419643B (en)
PL (1) PL3697818T3 (en)
TW (2) TWI828593B (en)
WO (1) WO2019017499A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3697818T3 (en) * 2017-10-19 2025-03-24 F. Hoffmann-La Roche Ag Treatment of CD20-positive B-cell lymphoma with obinutuzumab
AU2020356896B2 (en) * 2019-10-04 2026-07-30 Chugai Seiyaku Kabushiki Kaisha Inhibitor of cell proliferation in obinutuzumab resistant CD20-positive cancer, and medicinal composition, medicine, production, method for inhibiting cell proliferation, therapeutic method, type II anti-CD20 antibody, compounds, combination of same, enhancer and inducer, each relating thereto
WO2023042679A1 (en) 2021-09-17 2023-03-23 キヤノン株式会社 Power transmission device and power reception device

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE038955T2 (en) 2003-11-05 2018-12-28 Roche Glycart Ag Antigen binding molecules with increased Fc receptor binding affinity and effector function
WO2009080541A1 (en) 2007-12-21 2009-07-02 F. Hoffmann-La Roche Ag Antibody formulation
RS63364B1 (en) 2014-08-11 2022-07-29 Acerta Pharma Bv THERAPEUTIC COMBINATIONS OF BTK INHIBITORS, PD-1 INHIBITORS AND/OR PD-L1 INHIBITORS
US11149091B2 (en) * 2015-12-09 2021-10-19 Cedars-Sinai Medical Center Methods for treating nephrotic syndrome
CN108395482B (en) * 2017-02-08 2021-02-05 西比曼生物科技(香港)有限公司 Construction of targeting CD20 antigen chimeric antigen receptor and activity identification of engineered T cell thereof
US12377681B2 (en) 2017-07-21 2025-08-05 The Yokohama Rubber Co., Ltd. Pneumatic tire
PL3697818T3 (en) * 2017-10-19 2025-03-24 F. Hoffmann-La Roche Ag Treatment of CD20-positive B-cell lymphoma with obinutuzumab

Also Published As

Publication number Publication date
WO2019017499A2 (en) 2019-01-24
MX2020003418A (en) 2020-07-20
CN120983618A (en) 2025-11-21
TWI828593B (en) 2024-01-01
TW202342099A (en) 2023-11-01
JP2019528282A (en) 2019-10-10
JP6860652B2 (en) 2021-04-21
KR20200067196A (en) 2020-06-11
TW201922284A (en) 2019-06-16
JP2021152002A (en) 2021-09-30
EP3697818B1 (en) 2024-11-27
CA3079374A1 (en) 2019-01-24
KR20240157135A (en) 2024-10-31
IL273909B1 (en) 2025-08-01
BR112020007731A2 (en) 2020-10-20
IL273909A (en) 2020-05-31
WO2019017499A3 (en) 2019-02-21
EP4520347A3 (en) 2025-06-04
EP4520347A2 (en) 2025-03-12
US20250026847A1 (en) 2025-01-23
MX419643B (en) 2025-01-14
KR20260011191A (en) 2026-01-22
IL273909B2 (en) 2025-12-01
US12129304B2 (en) 2024-10-29
MX2024009217A (en) 2024-11-08
KR102766089B1 (en) 2025-02-13
JP7370357B2 (en) 2023-10-27
TWI805630B (en) 2023-06-21
AU2025205481A1 (en) 2025-08-07
KR102906969B1 (en) 2026-01-05
PL3697818T3 (en) 2025-03-24
AU2018303836B2 (en) 2025-04-17
US20200299398A1 (en) 2020-09-24
ES3005784T3 (en) 2025-03-17
CN111212854A (en) 2020-05-29
AU2018303836A1 (en) 2020-05-14
EP3697818A2 (en) 2020-08-26

Similar Documents

Publication Publication Date Title
JP2011511072A5 (en)
RU2018120377A (en) PRE-FILLED PHARMACEUTICAL PACKING CONTAINING A LIQUID COMPOSITION BASED ON VEGF ANTAGONIST
JP7491220B2 (en) Cancer treatment in combination with immune checkpoint inhibitors and FOLFIRINOX therapy
IL263110B (en) Combination therapy with notch and pd-1 or pd-l1 inhibitors
HRP20230504T1 (en) Activin-actrii antagonists and uses for treating myelodysplastic syndrome
JP2019514974A5 (en)
JP2018520094A5 (en)
JP2010515709A5 (en)
CN108601831A (en) Use of an anti-PD-1 antibody combined with a VEGFR inhibitor in the preparation of a drug for treating cancer
CN102006875A (en) Use of picoplatin and bevacizumab to treat colorectal cancer
EP4549467A2 (en) Administration of hypoxia activated prodrugs in combination with immune modulatory agents for treating cancer
IL273909B1 (en) Treatment of CD20-positive B-cell lymphoma with obinutuzumab
RU2020134307A (en) MELFLUFENE DOSING REGIMES FOR CANCER
JP2025508786A5 (en)
JP2021152002A5 (en)
TW202227089A (en) Combination therapy for the treatment of pik3ca mutant cancer
JP2023539625A5 (en)
JP2022501332A5 (en)
JP2017527551A5 (en)
Kim et al. Multicenter nonrandomized trial of ramosetron versus palonosetron in controlling chemotherapy-induced nausea and vomiting for colorectal cancer
Wolf et al. Peripheral administration of antithymocyte globulins: a review of current literature
CN102327599A (en) Be used to treat the compositions and the method for myelodysplastic syndrome
Cohn Prevention strategies for mycobacterium avium-intracellulare complex (MAC) infection: A review of recent studies in patients with AIDS
JP2020172471A (en) Pharmaceutical composition containing humanized anti-human CD26 antibody
Starr Isatuximab plus RVd Combination Achieves High Rates of No MRD in Patients with Multiple Myeloma.